Clinical trial · Interventional
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
Treatment of Relapsed/Refractory Acute Myeloblastic Leukemia(AML) by Infusion of Donor High Dose Allogeneic Mismatched Hematopoietic Stem Cells After Chemotherapy
NCT03080922CI-TRIAL-00026755unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myeloid | Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hematopoietic stem cell | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- hematopoietic stem cell
- description
- high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
- interventionNames
- Biological: hematopoietic stem cell
Primary outcomes (1)
- measure
- complete remission rate
- timeFrame
- 2 months
Secondary outcomes (4)
- measure
- Disease-free survival
- timeFrame
- 2 years
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with relapsed and/or refractory AML * Estimated life expectancy ≥ 12 weeks (according to investigator's judgment) * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 Exclusion Criteria: * Previous treatment with investigational gene or cell therapy medicine products * Any uncontrolled active medical disorder that would preclude participation as outlined
References
Publications (0)
Data not yet available
No reference posted for this study.